EQA uses comparisons among laboratories to confirm laboratory ability. As a matter of fact, it refers to the verification activity that evaluates, supervises and confirms the laboratory ability to ensure they maintain high testing capabilities. By participating in EQA program, it issues the evidence to evaluate whether the laboratory data are reliable and valid. Since the Ministry of Health started the EQA of PB fetal chromosome aneuploid (T21, T18 and T13) high-throughput sequencing in 2014, it has improved the service quality of all such laboratories in China. After years of making clinical sample testing and providing excellent service, Find Bio-Tech now owns the complete, regulated and high-quality laboratory gene testing techs, thus becoming a major force of in NIPT. 

As high-throughput sequencing technology develops rapidly and is put into clinical applications, Find Bio-Tech keeps following national policies and regulations and works hard to push forward development of gene testing. Taking the meticulous and responsible attitude, Find Bio-Tech ensures the efficiency and accuracy of each sample in gene testing, and is dedicated to promoting the safe, accurate and rapid NIPT, genetic analysis of folic metabolism disorder, gene testing for single-gene inheritance disease, PGS/PGD, chromosome abnormality testing, newborn inheritance metabolism disease testing and other testing service related to high-quality child birth and pregnancy for clinical use for the public. At the same time, it also provides genetic testing services for individual medicines such as cancer targeted drugs, tumor chemotherapeutics, anti-high-blood-pressure medicines, anti-high-blood-sugar medicines, and anti-high-blood-fat medicines.